Upfront therapy of acute myeloid leukemia

Jenna Canzoniero, Bhavana Bhatnagar, Maria R. Baer, Ivana Gojo

Research output: Contribution to journalArticle

Abstract

Acute myeloid leukemia is a clinically and biologically heterogeneous disease. Standard induction chemotherapy, consisting of cytarabine and an anthracycline, has not changed substantially over several decades, and outcomes remain suboptimal, particularly in older patients. Many genetic and molecular changes have been identified that guide selection of post-remission therapy and for which targeted therapies are beginning to be developed and tested. These research efforts are resulting in gradual improvement in outcomes. We will review here recent advances in induction chemotherapy, including anthracycline dose intensification in younger patients, treatment selection and use of novel agents in upfront therapy for older patients, and risk-adapted post-remission therapy.

Original languageEnglish (US)
Pages (from-to)361-370
Number of pages10
JournalCurrent Oncology Reports
Volume13
Issue number5
DOIs
Publication statusPublished - Oct 2011
Externally publishedYes

    Fingerprint

Keywords

  • Acute myeloid leukemia
  • Chemotherapy
  • Novel drugs
  • Transplant

ASJC Scopus subject areas

  • Oncology

Cite this